

This is a repository copy of Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/198949/</u>

Version: Submitted Version

Preprint:

Leary, S. orcid.org/0000-0002-6966-2294, Gaudieri, S. orcid.org/0000-0001-6873-0198, Parker, M.D. orcid.org/0000-0003-2999-3870 et al. (17 more authors) (Submitted: 2021) Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level. [Preprint - bioRxiv] (Submitted)

https://doi.org/10.1101/2020.04.10.029454

© 2021 The Author(s). For reuse permissions, please contact the Author(s).

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/ bioRxiv preprint doi: https://doi.org/10.1101/2020.04.10.029454; this version posted August 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1	Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant
2	in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at
3	both protein and RNA level
4	
5	Shay Leary ¹ ¶, Silvana Gaudieri ^{1,2,3} ¶, Matthew D. Parker ⁴ ¶, Abha Chopra ¹ , Ian James ¹ , Suman
6	Pakala ³ , Eric Alves ² , Mina John ^{1,5} , Benjamin B. Lindsey ^{6,7} , Alexander J Keeley ^{6,7} , Sarah L.
7	Rowland-Jones ^{6,7} , Maurice S. Swanson ⁸ , David A. Ostrov ⁹ , Jodi L. Bubenik ⁸ , Suman Das ³ ,
8	John Sidney ¹⁰ , Alessandro Sette ^{10,11} , COVID-19 Genomics UK (COG-UK) consortium,
9	Thushan I. de Silva ^{6,7*} , Elizabeth Phillips ^{1,3*} , Simon Mallal ^{1,3#*}
10	
11	¹ Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western
12	Australia, Australia.
13	² School of Human Sciences, University of Western Australia, Crawley, Western Australia,
14	Australia.
15	³ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical
16	Center, Nashville, Tennessee, USA.
17	⁴ Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, The University of
18	Sheffield, Sheffield, UK.
19	⁵ Department of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia,
20	Australia.
21	⁶ Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
22	⁷ Department of Infection, Immunity and Cardiovascular Disease and The Florey Institute for
23	Host-Pathogen Interactions, Medical School, University of Sheffield, Sheffield, UK.
24	⁸ Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the
25	Genetics Institute, University of Florida, Gainesville, Florida, USA.
	1

26	⁹ Department	of Pathology,	Immunology	and Laboratory	Medicine,	University	of Florida,
	2	01 1 0000000000000000000000000000000000		and Ducolutor		0	01 1 10110

- 27 Gainesville, Florida, USA.
- ¹⁰Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La
- 29 Jolla, California, USA.
- 30 ¹¹Department of Medicine, Division of Infectious Diseases and Global Public Health,
- University of California, San Diego, La Jolla, California, USA.

32

- ³³[¶]These authors contributed equally to this work.
- ^{*}These authors also contributed equally to this work.

35

- 36 [#]Corresponding author
- 37 Prof. Simon Mallal
- 38 Email: s.mallal@vumc.org

39

- 40 Keywords: COVID-19; SARS-CoV-2; homologous recombination; sub-genomic RNA
- 41 transcript; transcription-regulating sequence; viral polymorphism

43 Abstract

Background: Genetic variations across the SARS-CoV-2 genome may influence 44 transmissibility of the virus and the host's anti-viral immune response, in turn affecting the 45 frequency of variants over-time. In this study, we examined the adjacent amino acid 46 polymorphisms in the nucleocapsid (R203K/G204R) of SARS-CoV-2 that arose on the 47 background of the spike D614G change and describe how strains harboring these changes 48 became dominant circulating strains globally. Methods: Deep sequencing data of SARS-49 CoV-2 from public databases and from clinical samples were analyzed to identify and map 50 genetic variants and sub-genomic RNA transcripts across the genome. Results: Sequence 51 52 analysis suggests that the three adjacent nucleotide changes that result in the K203/R204 variant have arisen by homologous recombination from the core sequence (CS) of the leader 53 transcription-regulating sequence (TRS) rather than by stepwise mutation. The resulting 54 55 sequence changes generate a novel sub-genomic RNA transcript for the C-terminal dimerization domain of nucleocapsid. Deep sequencing data from 981 clinical samples 56 confirmed the presence of the novel TRS-CS-dimerization domain RNA in individuals with 57 the K203/R204 variant. Quantification of sub-genomic RNA indicates that viruses with the 58 K203/R204 variant may also have increased expression of sub-genomic RNA from other 59 60 open reading frames. Conclusions: The finding that homologous recombination from the TRS may have occurred since the introduction of SARS-CoV-2 in humans resulting in both 61 coding changes and novel sub-genomic RNA transcripts suggests this as a mechanism for 62 63 diversification and adaptation within its new host.

64

66 Introduction

It is believed SARS-CoV-2 originated from a bat coronavirus transmitted to humans, likely 67 via an intermediate host such as a pangolin, acquiring a furin-cleavage site in the process. 68 This new motif allows cleavage at the boundary of the S1 and S2 domains of the spike 69 protein in virus-producing cells (1). A SARS-CoV-2 variant in the spike protein, D614G (B.1 70 lineage), emerged early in the epidemic and has rapidly became dominant in virtually all 71 areas of the world where it has circulated (2). Several studies have shown this variant to be 72 associated with higher viral RNA levels in the upper respiratory tract, higher titers in 73 pseudoviruses in-vitro (2, 3) and increased infectivity (4, 5). More recently, emerging 74 lineages from this genetic background (B.1.1.7 - 'Alpha or UK variant', B.1.351 - 'Beta or 75 South African variant', or B.1.617.2 - 'Delta variant') have been identified with reported 76 rapid local expansions of these viruses. 77

78

The diversification of coronaviruses can occur via point mutations and recombination events 79 (6, 7) that can result in increased prevalence due to selective advantage related to increased 80 infectiousness and transmission of the virus or by chance. Evidence of viral adaptation to 81 selective pressures as a virus spreads among diverse human populations has important 82 83 implications for the ongoing potential for changes in viral fitness over time, which in turn may impact transmissibility, disease pathogenesis and immunogenicity. Furthermore, the 84 functional impact of new genetic changes need to be considered in the performance of 85 diagnostic tests, ongoing public health measures to contain infection around the world and 86 the development of universal vaccines and antiviral therapies including monoclonal 87 antibodies. 88

Here we examined a variant of SARS-CoV-2 that emerged within the subset of sequences 90 91 harboring the D614G variant and contains three adjacent nucleotide changes spanning two residues of the nucleocapsid protein (R203K/G204R; B.1.1 lineage) that has resulted in a 92 novel sub-genomic RNA transcript. Sequence analysis suggests these changes are the result 93 of homologous recombination from the core sequence (CS) of the leader transcription-94 regulating sequence (TRS). This event introduced a new TRS between the RNA binding and 95 dimerization domains of nucleocapsid providing the template for the generation of a novel 96 sub-genomic RNA transcript. Further novel sub-genomic RNA transcripts arising in 97 association with incorporation of leader sequence and TRS were also observed, suggesting 98 99 homologous recombination from this region as a potential mechanism for SARS-CoV-2 diversification and adaptation within its new host. 100

102 Methods

103 Study Design

This study utilized deposited SARS-CoV-2 genomic sequences in public databases, with a further 981 Oxford Nanopore Technology genomes and clinical metadata from Sheffield, UK, as a validation set, to identify and map genetic variants and sub-genomic RNA transcripts across the genome. Accession numbers and links to datasets are in Supplementary Material.

109

110 SARS-CoV-2 sequence generation from patients with COVID-19

111 SARS-CoV-2 sequences, with matched clinical metadata, were generated using samples taken for routine clinical diagnostic use from 981 individuals presenting with COVID-19 112 disease to Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. This work 113 was performed under approval by the Public Health England Research Ethics and 114 Governance Group for the COVID-19 Genomics UK consortium (R&D NR0195). 115 Following extraction, samples were processed using the ARTIC Network SARS-CoV-2 116 protocol. After RT-PCR, SARS-CoV-2 specific PCR and library preparation with Oxford 117 Nanopore LSK-109 and barcoding expansion packs NBD-104 and NBD-114 samples were 118 sequenced on an Oxford Nanopore GridION X5 using R9.4.1D flow cells. Bases were called 119 with either fast or high accuracy guppy with demultiplexing enabled and set to --require-120 both-ends. Samples were then analyzed using ARTIC Network pipeline v1.1.0rc1. 121

122

123 SARS-CoV-2 sequence acquisition from public repositories

Complete SARS-CoV-2 genome sequences were downloaded from the GISAID EpiCoV
 repository on 24th January 2021 (<u>https://www.gisaid.org/</u>). The complete dataset of 455,774
 sequences with coverage across the genome were aligned in CLCbio Genomics Workbench

12 (QIAGEN Bioinformatics) to the GenBank reference sequence NC 045512.2. Aligned 127 sequences were exported in FASTA format and imported into Visual Genomics Analysis 128 Studio (VGAS), an in-house program for visualizing and analyzing sequencing data 129 (http://www.iiid.com.au/software/vgas). The chronological appearance of the sequences was 130 generated using the collection dates for each of the sequences. Of note, our current 131 knowledge of the global circulating variants is dependent on the ability of laboratories in 132 different countries to deposit full genome length SARS-CoV-2 sequences and may be subject 133 to ascertainment bias. As such, the frequencies of specific variants shown may not reflect the 134 size of the outbreak. However, the data does provide the opportunity to predict the presence 135 136 of specific variants in areas given the known epidemiology within different countries and regions. A subset of subjects also had individual deep sequence reads deposited in the 137 Sequence Read Archive (SRA) at www.ncbi.nlm.nih/sra. These sequence reads were 138 downloaded and aligned as indicated above. 139

140

141 Identification of amino acid substitutions

Codon usage output allowed for identification of amino acid substitutions across the SARS-142 Cov-2 genome. A cut-off of 5% frequency within the consensus SARS-CoV-2 protein 143 144 sequences was set to obtain the codon usage across all sequences and as shown in S1 Table. The viral polymorphisms detected are present in viral variants sequenced using different 145 NGS platforms (e.g. nanopore, Illumina) and the Sanger-based sequencing method making it 146 unlikely that the new changes are sequence or alignment errors. In addition, different 147 laboratories around the world have deposited sequences with these polymorphisms in the 148 database and examination of individual sequences in the region failed to uncover obvious 149 insertions/deletions likely representing alignment issues or homopolymer slippage. 150

152 HLA peptide binding prediction

The region containing the adjacent amino acid polymorphisms in the nucleocapsid was 153 8-14 divided into sliding windows of amino acids. NetMHC 4.0 154 (http://www.cbs.dtu.dk/services/NetMHC/) NetMHCpan 40 155 and (http://www.cbs.dtu.dk/services/NetMHCpan/) with default settings were utilized to predict 156 HLA-class I binding scores and binding differences across all HLA class-I alleles for the 157 original 2003 SARS and current SARS-CoV-2 sequences harboring the R203/G204 and 158 K203/R204 polymorphisms in the nucleocapsid (output listed in S2 Table). 159

160

161 HLA peptide binding assays

MHC was purified from the Steinlin EBV transformed homozygous cell line (IHWG ID: 162 9087; A*01:01, B*08:01 and C*07:01) using the B123.2 (anti-HLA-B, C) and W6/32 (anti-163 class I) monoclonal antibodies, and classical MHC-peptide inhibition of binding assays 164 performed, as previously described (8). To develop an HLA C*07:01-specific binding assay, 165 the IEDB was utilized to identify candidate peptides reported as HLA-C*07:01 epitopes or 166 eluted ligands. One peptide (3424.0028; sequence IRSSYIRVL, Macaca mulatta and Homo 167 sapiens DNA replication licensing factor MCM5 289-297) was radiolabeled and found in 168 169 direct binding assays to yield a strong signal with as little as 0.5 nM MHC. Subsequent inhibition of binding assays established that 3424.0028 bound with an affinity of 0.21 nM. To 170 establish that the putative assay was specific for C*07:01, and not co-purified B*08:01, two 171 additional peptides previously reported as HLA-C*07:01 ligands were also tested, with one 172 found to bind with high affinity (IC50 67 nM) and the other with intermediate (IC50 1600 173 nM). At the same time, a panel of known B*08:01 ligands were not found to have the 174 capacity to inhibit binding of radiolabeled 3424.0028 (S3 Table). By contrast, when the same 175 panel of peptides was tested in the previously validated B*08:01 assay (9), 3424.0028 was 176

- found to bind with about 1500-fold lower affinity, all of the known B*08:01 ligands bound
- with IC50s <10 nM, and the C*07:01 ligands with affinities >1000 nM.
- 179

180 Sub-genomic RNA classification & quantification in the Validation Dataset

We developed a tool, "periscope" (v0.0.0), to classify and quantify sub-genomic RNA in the Sheffield ARTIC network Nanopore dataset (10). The tool can be downloaded from git-hub at <u>https://github.com/sheffield-bioinformatics-core/periscope</u>. Briefly, this tool uses local alignment to identify putative sub-genomic RNA supporting reads and uses genomic reads from the same amplicon to normalize.

186

187 RNA structure modeling

The RNAfold program from the ViennaRNA Web Server (http://rna.tbi.univie.ac.at/) was 188 used for structural predictions using the default settings and the minimum free energy 189 structures were acquired using the base-pairing probability color scheme. The Dot-bracket 190 folding notations were obtained for each of the R203K/G204R sequences and used for 191 Junction Explorer (nature.njit.edu/biosoft/Junction-Explorer/) and CHS-align 192 (nature.njit.edu/biosoft/CHSalign/). 193

195 Statistical Analysis

Fisher exact test was used to compare the proportion of subjects with specific sub-genomic RNA transcripts. P values less than 0.05 was used as the statistical threshold. Comparisons between sub-genomic and genomic RNA expression in R203/G204 compared to K203/R204 containing sequences was made using the Mann-Whitney U test, corrected for multiple comparisons using the Holm method. Logistic and linear regression modeling used to explore the impact of K203/R204 and other co-variates on hospitalization, CT values and subgenomic RNA expression.

203

205 Results and Discussion

Adjacent nucleocapsid polymorphisms emerged from the existing spike protein D614G variant

We utilized publicly available SARS-CoV-2 sequences from the GISAID database (available 208 on the 24th of January 2021; www.gisaid.org) to identify amino acid polymorphisms arising 209 in global circulating forms of the virus in relation to region and time of collection. Of the 210 211 455,774 circulating variants there were 29 amino acid polymorphisms present in >5% of the deposited sequences (of a total of 9413 sites; S1 Table) including the spike D614G variant 212 (B.1 lineage) that emerged early in the pandemic and the adjacent R203K/G204R variants 213 214 (B.1.1 lineage) in the nucleocapsid protein (11) that formed one of the main variants emerging from Europe in early 2020. As of the end of January 2021, the K203/R204 variant 215 comprises 37.4% of globally reported SARS-CoV-2 sequences (Fig 1) and almost 216 217 exclusively occurs on the D614G genetic background (S4 Table).

218

Although the D614G change rapidly increased in prevalence in almost all regions, the 219 prevalence rates of the K203/R204 subset of the D614G variant are variable in different 220 geographic areas and over-time (Fig 2). For example, an almost complete replacement of 221 222 D614 by G614 was noted in South America between March and April 2020 and a similar replacement pattern was seen with the K203/R204 variant most marked in Chile, Argentina 223 and Brazil (12). A closer examination of the deposited sequences in the UK shows the 224 K203/R204 variant increasing in prevalence early in 2020 but the second wave later in the 225 year shows a shift in the proportion of deposited sequences with the R203/G204 subset of the 226 D614G variant (B.1.177 lineage) until the recent appearance of the B.1.1.7 'Alpha or UK 227 variant' that harbors the K203/R204 polymorphisms (S1 Fig and S4 Table); supporting a 228 likely increased infectivity of this variant. 229

230

Amino acid polymorphisms due to three adjacent nucleotide changes in the nucleocapsid likely due to homologous recombination

Of the publicly available sequences examined with the two amino acid polymorphisms 233 K203/R204, all showed the three adjacent nucleotide changes from AGG GGA to AAA 234 CGA. There was no differential codon usage for the K203/R204 variant in the database. 235 However, there was evidence of low frequency alternative codon usage for arginine at 203 236 (AGA) for the R203/G204 variant and for lysine (AAG) at 203 for the K203/G204 variant 237 (S5 Table). Overall, circulating variants that contain the intermediate codon as the consensus 238 239 that could facilitate a single step from the AGG arginine codon to the AAA lysine codon at position 203 appear rare among captured variants to date (S5 Table). Furthermore, a K203 240 polymorphism alone was seen in 0.3% and an R204 polymorphism alone seen in only 0.02% 241 of sequences (S5 Table). The low frequency K203/L204 and K203/P204 variants are both 242 one nucleotide step from the K203/R204 variant, have been deposited into the public 243 databases (November 2020) well after the emergence of the K203/R204 variant (February 244 2020) and accordingly likely arose from this genetic background. 245

246

247 The rapid emergence of closely linked polymorphisms in viruses can also reflect strong selection pressure on this region of the genome in which the original mutation incurred a 248 replicative capacity, or other fitness cost, which could be restored by a linked compensatory 249 250 mutation. Evidence for such adaptations with closely linked compensatory mutations are known to occur under host immune pressure as is well established for other RNA viruses 251 such as HIV (13-15) and Hepatitis C virus (16). In the absence of anti-viral treatment, these 252 viruses have such a high rate of viral replication, error-prone polymerases and lack associated 253 proofreading, mismatch repair, and other nucleic acid repair pathways generating a swarm of 254

viral variants with ongoing recombination between variants (in the case of HIV) being 255 generated continuously. As a result, selection pressure exerted by immune responses or other 256 selective pressures effectively operate on each separate residue independently (15). In 257 contrast, coronaviruses encode proofreading machinery and have a propensity to adapt by 258 homologous recombination between viruses (6) rather than necessarily by classic stepwise 259 individual mutations driven by selective pressures effectively operating on individual viral 260 residues. Furthermore, a simulation based on the nucleocapsid genomic region and allowing 261 up to 10 random mutations indicates the likelihood of observing three consecutive nucleotide 262 changes is less than 0.0005. These findings argue against stepwise change of the nucleotides 263 264 for the R203K/G204R variant.

265

The introduction of the AAACGA motif by homologous or heterologous recombination is a more parsimonious mechanistic explanation and would have immediately resulted in both an R to K change and adjacent G to R change at the positions 203 and 204, respectively. It is critical to determine if the introduction of the AAACGA motif has induced any replicative or other fitness change for the virus as a result of either structural or functional changes in the RNA or the concomitant change of amino acids from R203/G204 to K203/R204 and any related structural or functional impact on the nucleocapsid protein.

273

274 SARS-CoV-2 itself as likely source for homologous recombination

To identify possible viral sources for homologous recombination with SARS-CoV-2, we initially performed a search of the motif in the nucleocapsid in related beta coronaviruses from human and other species in the public databases and only found the presence of the R203/G204 combination. We performed a similar search in our metatranscriptome data generated from a cohort study consisting of 65 subjects of whom 43 had acute respiratory

infections and 22 were asymptomatic. From the data we assembled near complete and coding 280 complete viral genomes of the Coronavirus (NL63 - alpha, OC43 - beta, 229E - alpha), RSV 281 (A, B), Rhinovirus (A, B, C), Influenza (A - H3N2), and Bocavirus family. None of the alpha 282 coronaviruses had the R203/G204 or K203/R204 combination or indeed any variation at 283 these sites (n=14; sequence depth >3000). We then performed a search for stretches of 284 similarity using varying window sizes (>14 base-pair (bp) including the motif) in all 285 sequences. A 14bp window was selected as 14bp has been shown to be the minimum amount 286 of homology required for homologous recombination in mammalian cells (17). No significant 287 hits were identified. However, the AAACGA sequence encoding the K203/R204 amino acids 288 289 overlaps with the CTAAACGAAC motif of the leader transcription-regulating sequences (TRS; core underlined) (18) of SARS-CoV-2 itself and this core sequence motif is also found 290 near the start codon of the protein for surface glycoprotein (S), ORF3a, E, M, ORF6, ORF7a, 291 ORF8, ORF10 and nucleocapsid, in keeping with its known roles in mediating template 292 switching and discontinuous transcription (18). 293

294

295 Deep sequencing confirms quasi-species with the leader sequence linked to known or 296 introduced TRS region

Discontinuous transcription of SARS-CoV-2 results in sub-genomic RNA (sgRNA) transcripts containing 5'-leader sequence-TRS-start codon-ORF-3'. These RNA transcripts should also be captured from reads generated from NGS platforms. We therefore reasoned we should be able to find such sequences within deep sequencing reads at the sites of known sub-genomic regions (corresponding to the ORFs) and adjacent to position 203/204 of the nucleocapsid in subjects infected with the K203/R204 variant but not in those with the R203/G204 variant (Fig 3).

We searched for sgRNAs in sequence data generated from n=981 patients with COVID-19 305 306 based on the ARTIC network protocol (www.artic.network/ncov-2019; Fig 3) and subsequent Nanopore sequencing in Sheffield, UK. As expected, the most frequent sgRNA transcripts in 307 each subject, irrespective of variant, corresponded to the known regions containing the start 308 codon of the SARS-CoV-2 proteins (Fig 4A). However, out of a total of 550 K203/R204 309 sequences, 231 had evidence (>=1 read containing leader sequence at the novel TRS site) of 310 the non-canonical nucleocapsid sgRNA (42%) but only 1 out of a total of 431 R203/G204 311 subjects had evidence of the novel sgRNA (likely a false positive as described in S2 Fig). 312

313

314 We confirmed the presence of the novel non-canonical nucleocapsid sgRNA in 27/45 individuals with the K203/R204 variant but in none of 45 individuals with the R203/G204 315 variant (Fisher test, p=5.0e-11; S6 Table) from the sequence read archive (SRA) database 316 (www.ncbi.nlm.nih/sra). Interestingly, we also found the presence of 23 other non-canonical 317 sgRNA transcripts with the 5'-leader-TRS-start codon-3' at low frequency in the 90 subjects 318 (irrespective of variant) due to multiple adjacent changes to the consensus sequence across 319 the genome generating new core TRS motifs (including with minor mismatches) (S6 Table). 320 321 It should be noted that none of these changes are present in the consensus sequence of the 322 SARS-CoV-2 genomes downloaded and represent low frequency quasispecies within individuals. It does, however, suggest other instances of the introduction of the core 323 sequences from the leader TRS elsewhere in the SARS-CoV-2 genome. 324

325

326 SARS-CoV-2 viruses with K203/R204 are not associated with greater hospitalization 327 with COVID-19 or higher virus levels in the upper respiratory tract

328 The same dataset from COVID-19 patients in Sheffield, UK, was used to explore whether the

329 K203/R204 variant had any association with clinical outcome. The median age of this cohort 15

was 54 years (IQR 38 to 74) and 59.8% were female. Of these, 440 (44.9%) were 330 331 hospitalized COVID-19 patients and 42 (4.3%) subsequently required critical care support. A multivariable logistic regression model including 203/204 status, age and sex showed no 332 association of K203/R204 with hospitalization (OR 0.82, 95% confidence intervals (CI 0.58 -333 1.16), p=0.259). As expected, higher age and male sex were significantly association with 334 hospitalization with COVID-19 (OR 1.09, 95% CI 1.08 – 1.11, p <2e-16 for age and OR 335 4.47, 95% CI 3.13 – 6.43, p=2.91e-16 for male sex). Male sex, but not age or 203/204 status, 336 was associated with risk of critical care admission (S7 Table). 337

338

339 We explored whether K203/R204 was associated with greater virus levels in the upper respiratory tract as estimated by cycle threshold (CT) values from the diagnostic RT-PCR. As 340 day of illness will impact CT value, we focused on a subset of the cohort (n=478) where this 341 information was available (all non-hospitalized patients, median symptom day 3, range 1 - 13342 days). Data were analyzed with sequences stratified by spike 614 and nucleocapsid 203/204 343 status (D614/R203/G204, G614/R203/G204 and G614/K203/R204). Multivariable linear 344 regression models showed no impact of G614/K203/R204 compared to G614/R203/G204 345 status on CT values (p= 0.83, S6B Table), but as expected, later day of symptom onset was 346 significantly associated with higher CT values, therefore lower viral load (S8 Table, 347 p=2.05E-05). Consistent with recent findings (2), presence of a spike D614G variant was 348 significantly associated with lower CT values (higher viral loads) in the same subset of 349 individuals, even when day of illness at sampling is included in the model (S8A Table, 350 D614/R203/G204 vs G614/R203/G204, p=0.00011, Fig 5A & B). 351

352

353 SARS-CoV-2 viruses with K203/R204 have evidence of higher sub-genomic RNA 354 expression

We hypothesized that the amount of sgRNA at each of the ORF TRS positions in the SARS-355 356 CoV-2 genome in ARTIC nanopore sequencing data could serve as a proxy for expression levels of each of the ORFs due to their positions in the amplicons (Fig 3). To test this 357 hypothesis we developed a tool, periscope (19), which quantifies the number of sgRNA and 358 genomic RNA reads at each ORF TRS position in ARTIC network nanopore sequencing 359 data. We applied periscope to the 981 sequences in the Sheffield validation dataset. To 360 361 control for the sequencing depth differences evident between amplicons, we determined the amplicon that shares the 3' primer with the sgRNA reads and used the total count of genomic 362 RNA at this amplicon to calculate the proportion of sgRNA for each ORF. The N ORF 363 364 sgRNA is expressed at high levels in all samples. ORF10 sgRNA was absent as others have shown (20). A significant increase in sgRNA levels for several ORFs in samples with 365 K203/R204 compared to R203/G204 samples is apparent (Fig 4B). N is the most striking 366 example (Fig 4C, Mann-Whitney U test p value, adjusted for multiple testing p = 2.06e-37), 367 but sgRNA from ORFs E, M and ORF6 are also significantly increased. There is no 368 significant difference in genomic RNA levels (Fig 4D, normalized to total mapped reads) 369 between these two groups. 370

371

372 As discussed above, the K203/R204 variants appear to have emerged within the subset of SARS-CoV-2 sequences with a D614G variant in the spike protein, which has been 373 associated with infections with a higher viral load in the upper respiratory tract. To explore 374 whether the differences between K203/R204 and R203/G204 sequences in sgRNA quantities 375 were due to D614 compared to G614 variant differences, we repeated the comparisons 376 following further stratification of sequences. Interestingly, G614/R203/G204 variants showed 377 lower total sgRNA expression than D614/R203/G204 samples (S3 Fig). Of note, sgRNA for 378 spike (S), membrane (M) and envelope (E) ORFs were significantly higher in samples with 379 17

D614/R203/G204 compared to those with G614/R203/G204 (adjusted p values 1.02e-4 for S, 0.0495 for M and 0.00696 for E). Total sgRNA in G614/K203/R204-containing samples was still significantly higher than in G614/R203/G204 samples (S3A Fig, Mann-Whitney U test p value, adjusted for multiple testing p = 3.5e-6). Similar increases in some individual ORF sgRNA quantities in G614/K203/R204 compared to G614/R203/G204 sequences were also seen, most notably for nucleocapsid (S3B Fig, adjusted p value 1.34e-12).

386

To ensure that the increase in sgRNA in K203/R204-containing sequences was not due to 387 confounding by differences in sampling date compared to date of symptom onset, we 388 389 evaluated the impact of K203/R204 and day of illness on sgRNA expression in a multivariable linear regression model using the subset of 478 sequences described above 390 (stratified by D614/R203/G204, G614/R203/G204 and G614/K203/R204 status). Higher 391 sgRNA levels were significantly associated with later day from symptom onset (S9 Table, 392 p=9.9E-08). G614/R203/G204 compared to D614/R203/G204 was again associated with a 393 reduction in sgRNA levels (p=0.011, S9A Table), whereas a K203/R204 change on the 394 background of spike G614-containing sequences was associated with a significant increase in 395 sub-genomic RNA (p=4.51E-05, S9B Table). Spike canonical sub-genomic RNA was higher 396 397 in D614/R203/G204 samples, whereas nucleocapsid canonical sub-genomic RNA was higher in G614/K203/R204 samples (Fig 5C and D, S3 Fig). 398

399

400 RT-PCR assays have been developed to directly assess sub-genomic mRNA (sgRNA) as a 401 measure of replicative intermediates of SARS-CoV-2 representing putative replication in 402 cells rather than RNA packaged in virions or residual viral RNA (21, 22). A decline in 403 sgRNA in sputum typically occurs from day 10 to 11 after onset of symptoms (22). Our 404 finding that a variant can emerge that is associated with a novel sub-genomic RNA or may differentially impact the level of different sgRNAs suggest that the viral sequences should be
analyzed to ensure the primers or probes used are appropriate and analysis of short read deep
sequences with the periscope tool considered to help interpret results obtained from different
variants.

409

410 Potential impact of introduced TRS sequences on RNA structure

411 Modeling of the region around the mRNA encoding position 203 and 204 of the nucleocapsid using RNAfold (23) predicts the presence of a three-way junction in the RNA (S4 Fig), 412 which was also predicted using Junction-Explorer (24). Three-way junction motifs are 413 414 common throughout biology and are found both in pure RNAs, such as riboswitches or ribozymes, and in RNA-protein complexes, including the ribosome (25). RNA three-way 415 junctions are often stabilized via terminal loop interactions with distant tertiary contacts 416 while the junctions act like flexible hinges. These attributes allow these structures to sample 417 unusual conformational spaces and they often form platforms for interactions with other 418 molecules such as proteins, RNAs or small molecule ligands (25), and these folds often have 419 an essential role in either the function or assembly of the molecules in which they are 420 contained. 421

422

RNAfold predicts the mutation from AGGGGA to AAACGA strongly disrupts this structure as the lengths of the predicted helices and each of the junctions are altered and the stability of Helix 2 is undermined (S4 Fig). A comparison of the two-modeled sequences using CHSalign (26) also indicates that none of the junctions are maintained. Given these widespread alterations, this modeling predicts that the AGGGGA to AAACGA mutation would have a strong impact on the local RNA structure of this region, and likely impacts the normal function of this three-way junction motif. Interestingly, the RNA modeling shown in 430 S4 Fig also suggests that pairing of specific nucleotides to maintain these RNA structures 431 may require the preferential codon usage by RG (AGGGGA) and KR (AAACGA) and be a 432 contributory factor to preferential codon usage in RNA viruses more generally even in 433 protein coding regions.

434

While it is not possible to determine the impact of this proposed structural alteration on 435 SARS-CoV-2 without a defined function for this structure, there are precedents where minor 436 changes in a three-way junction have large functional consequences for their host viruses. For 437 example, Flaviviruses such as Dengue and West Nile virus utilize the host cell machinery to 438 439 degrade viral genomes until they encounter structures near the 3' end that are resistant to XRN1 5'-3' exonuclease (27). The resulting small flaviviral RNAs (sfRNAs) are non-coding 440 RNAs that induce cytopathicity and pathogenicity. The resistance of sfRNA to XRN1 is 441 dependent on the structure of a three-way junction and a single nucleotide change at the 442 junction alters the fold sufficiently to prevent the accumulation of disease-related sfRNAs. 443 Thus, small changes at the nucleotide level can have profound functional consequences for 444 viral RNA three-way junctions. 445

446

447 Lack of evidence that the RG to KR change at positions 203 and 204 of nucleocapsid 448 was driven by HLA-restricted immune selective pressure

Selection of viral adaptations to polymorphic host responses mediated by T cells, NK-cells
and antibodies are well described for other RNA viruses such as HIV and HCV (15, 28).
HIV-1 adaptations to human leucocyte antigen (HLA)-restricted T-cell responses have also
been shown to be transmitted and accumulate over time (29, 30). As previously shown for
SARS-CoV, T-cell responses against SARS-CoV-2 are likely to target the nucleocapsid (31).
Notably, SARS-CoV-2 R203K/G204R polymorphisms modify the predicted binding of

putative HLA-restricted T-cell epitopes containing these residues (S2 Table). One of the 455 predicted T-cell epitopes is restricted by the HLA-C*07 allele; and we therefore considered 456 whether escape from HLA-C-restricted T-cell responses may conceivably confer a fitness 457 advantage for SARS-CoV-2, particularly in European populations where HLA-C*07 is 458 prevalent and carried by >40% of the population (www.allelefrequencies.net). However, 459 using HLA-C*07:01 purified from the Steinlin cell line (IHWG ID: 9087; A*01:01, B*08:01 460 and C*07:01) and the anti-HLA Class I B123.2 mAb in inhibition assays we were not able to 461 detect binding of either of the SARS-CoV-2 peptides SRGTSPARM or SKRTSPARM (S3 462 Table). We therefore have, as yet no evidence of any impact or selective advantage to the 463 virus at the protein level of a change at position 203/204 from the RG to KR residues. 464

465

466 SARS-CoV-2 and Host Adaptation: Implications for global viral dynamics, 467 pathogenesis and immunogenicity

Currently the possible functional effect(s) of the introduction of the AAACGA motif from the 468 leader TRS into the RNA encoding position 203 and 204 of the nucleocapsid at the RNA and 469 protein level are not known. TRS sites are usually intergenic and it has been assumed that 470 recombination events at such sites are more likely to be viable. It has also been shown 471 472 recently that recombination breakpoint hotspots in coronaviruses are more frequently colocated with TRS-B sites than expected (32). Our findings suggest that a novel TRS-B site 473 can be introduced in a recombination breakpoint from the leader TRS, and that this can occur 474 475 within an ORF and remain viable. The exact mechanism by which the AAA CGA codons could have been incorporated from the TRS-L into the nucleocapsid is not known but may 476 have first required the AAACGA to be captured from the TRS-L and then for replication to 477 be reinitiated at the nucleocapsid to generate a full-length genomic RNA. 478

The nucleocapsid protein is a key structural protein critical to viral transcription and 480 assembly (33), suggesting that changes in this protein could either increase or decrease 481 replicative fitness. The K203/R204 polymorphism is located between the RNA 482 binding/serine-rich domains and the dimerization structural domain (S5 Fig) in a part of the 483 protein that has not been characterized in terms of 3-dimensional structure. The sequence of 484 this region is not similar enough to solved structures to allow prediction of the influence of 485 the K203/R204 polymorphisms on the structure or function of the protein. However, it is 486 known that SARS-CoV-2 is exquisitely sensitive to interferons and that it depends on the 487 nucleocapsid and M proteins to maintain interferon antagonism (34, 35). Specifically the C 488 489 terminus (aa 362 to 422) of the nucleocapsid, which is predicted to be expressed at higher levels in those with the KR variant and novel sgRNA, has been shown to interact with the 490 SPRY domain of TRIM25 disturbing its interaction with CARDs of RIG-I inhibiting RIG-I 491 ubiquitination and Type 1 interferon signaling (36). Importantly the cells expressing the C-492 terminal nucleocapsid protein in that study produced lower viral titer, suggesting the 493 incorporation of this protein into the nucleocapsid may reduce the formation of functional 494 virus. This raises the possibility that any enhancement of inhibition of interferon signaling 495 associated with the novel K203/R204 sgRNA may be offset by less efficient replication, 496 497 potentially accounting for the lack of association with higher viral load in the upper respiratory tract and absence of epidemiologic evidence of increased transmission. It is also 498 possible that the increase in sgRNA directly inhibits RIG-I signaling and downstream Type I 499 interferon responses as has been described for Dengue serotype 2 (37). Finally, the central 500 region of coronavirus nucleocapsid (aa 117 to 268) has been shown to have RNA chaperone 501 activity that enhances template switching and efficient transcription possibly accounting for 502 the increase in sgRNA for the E and M proteins and ORF6 in KR-sequences compared to 503

504 RG-sequences (38). Note we cannot exclude that the novel sgRNA may also use the 505 downstream ATG in the ORF9c reading frame.

506

The adaptive potential of differential expression of sgRNAs is supported by a recent study by 507 Thorne and colleagues that demonstrates that the B.1.1.7 ('Alpha' or UK variant) isolate 508 containing the R203K/G204R substitutions is associated with enhanced antagonism of the 509 innate immune response (39). Specifically, this study showed that in-vitro infection of human 510 lung epithelial (Calu-3) cells by B.1.1.7 isolates showed diminished RNA and protein 511 512 expression of IFNB and reduced induction of interferon sensitive genes relative to other isolates without these defining mutations in the nucleocapsid (normalized for intracellular 513 viral RNA). This effect was independent of the reduced sensitivity to type I and III IFNs 514 described for isolates carrying the D614G spike mutation (40). Further evaluation of this 515 system showed that infection with the B.1.1.7 isolate resulted in significant changes in 516 protein expression of known innate immune regulators such as ORF9b (41), ORF6 (42) and 517 nucleocapsid (36, 43), as well as increased levels of the N* sgRNA described in this study 518 and was again confirmed to be unique to those isolates with the R203K/G204R mutations. 519 These increased levels of sgRNAs and protein support the findings in this study showing 520 increased sgRNA levels for N, ORF6 and N* in clinical samples from B.1.1.7-infected 521 subjects relative to subjects infected with other SARS-CoV-2 isolates. Interestingly, the 522 increased levels of ORF9b may be due to the D3L mutation in the nucleocapsid that we have 523 proposed to have arisen similarly to the R203G/G204R mutations and is associated with 524 525 increased levels of B.1.1.7 sgRNA encoding ORF9b in clinical samples (44).

The B.1.617.2 ('Delta') variant appears to be more transmissible even in the context of previous vaccination and is now replacing other variants. This variant has acquired an R203M substitution as a result of a single nucleotide change while retaining an arginine (G) at position 204. This raises the possibility that the residue 203 is critical to the interaction of nucleocapsid with TRIM25 decreasing the Type 1 interferon response or increases transmissibility in some other way (36).

533

Other contemporary concerns include the fall in antibody levels following infection or 534 vaccination, the potential limited durability of protection afforded by currently available 535 vaccines and the risk of reinfection by variants after vaccination (45, 46). At low levels of 536 antibodies, the lungs appear to remain relatively protected against severe disease presumably 537 by some combination of antibodies and amnestic responses restimulated by the time the lung 538 is involved. In contrast, the early establishment of infection in the upper respiratory tract 539 appears possible if antibody levels are low (47). We therefore postulate that variants that are 540 more effective in interfering with Type 1 interferon responses would be more transmissible, 541 but not necessarily cause severe disease in the context of waning immunity at an individual or 542 population level. 543

544

545 Conclusion

Marked viral diversity and adaptation of other RNA viruses such as HIV, HCV and influenza to host selective pressures have been a barrier to successful treatment and vaccination to date. Although SARS-CoV-2 is less diverse and adaptable, the D614G variant and the K203/R204 and Delta variants have emerged by either nucleotide mutation or homologous recombination during its rapid, widespread global spread and do appear to have functional impact. It will

551	therefore be critical to continue molecular surveillance of the virus and elucidate the
552	functional consequences of any newly emerging viral genetic changes to guide development
553	of diagnostics, antivirals and universal vaccines and to target conserved and potentially less
554	mutable SARS-CoV-2 elements. The ability of SARS-CoV-2 to introduce new TRS motifs
555	throughout its genome with the potential to introduce both novel sub-genomic RNA
556	transcripts and coding changes in its proteins may add to these challenges.

Acknowledgments: We thank colleagues at the Institute for Immunology and Infectious 561 Diseases, Murdoch University, Australia and the Department of Medicine, Division of 562 Infectious Diseases, Vanderbilt University Medical Center, USA. We would like to 563 acknowledge additional members of the Sheffield COVID-19 Genomic Group who 564 contributed to the generation of the sequence data: Adrienne Angyal, Rebecca L. Brown, 565 Laura Carrilero, Cariad M Evans, Luke R. Green, Danielle C. Groves, Katie J Johnson, Paul J 566 Parsons, David Partridge, Mohammad Raza, Rachel M. Tucker, Dennis Wang, Matthew D. 567 Wyles. Ethics approval and consent to participate (COG-UK CONSORTIUM; R&D 568 NR0195). 569

570 We thank the reviewers and editor for their helpful comments.

571

Funding Sources: SG, SL and EA were supported by a grant awarded by the National 572 Health and Medical Research Council (NHMRC; APP1148284). SM was supported by a 573 National Institutes of Health (NIH)-funded Tennessee Center for AIDS Research (P30 574 AI110527). MDP was funded by the NIHR Sheffield Biomedical Research Centre (BRC - IS-575 BRC-1215-20017). Sequencing of SARS-CoV-2 samples was undertaken by the Sheffield 576 COVID-19 Genomics Group as part of the COG-UK CONSORTIUM. COG-UK and 577 578 supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research 579 Limited, operating as the Wellcome Sanger Institute. TIdS is supported by a Wellcome Trust 580 581 Intermediate Clinical Fellowship (110058/Z/15/Z).

582

583 Conflicts of interests: The authors declare that they have no conflicts of interests.

584 References:

585

Zhang T, Wu O, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with 1. 586 the COVID-19 Outbreak. Curr Biol. 2020;30(7):1346-51 e2. Epub 2020/03/21. doi: 587 10.1016/j.cub.2020.03.022. PubMed PMID: 32197085; PMCID: PMC7156161. 588 2. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner 589 N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, 590 Freeman TM, de Silva TI, Sheffield C-GG, McDanal C, Perez LG, Tang H, Moon-Walker A, 591 Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. Tracking Changes in SARS-CoV-2 592 593 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020. Epub 2020/07/23. doi: 10.1016/j.cell.2020.06.043. PubMed PMID: 594 32697968; PMCID: PMC7332439. 595 3. Grubaugh ND, Hanage WP, Rasmussen AL. Making Sense of Mutation: What 596 D614G Means for the COVID-19 Pandemic Remains Unclear. Cell. 2020. Epub 2020/07/23. 597 doi: 10.1016/j.cell.2020.06.040. PubMed PMID: 32697970; PMCID: PMC7332445. 598 4. Yurkovetskiy L, Pascal KE, Tompkins-Tinch C, Nyalile T, Wang Y, Baum A, Diehl 599 WE, Dauphin A, Carbone C, Veinotte K, Egri SB, Schaffner SF, Lemieux JE, Munro J, 600 601 Sabeti PC, Kyratsous C, Shen K, Luban J. SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding 602 domain. bioRxiv. 2020. Epub 2020/07/09. doi: 10.1101/2020.07.04.187757. PubMed PMID: 603 32637944; PMCID: PMC7337374. 604 5. Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. 605 The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases 606

infectivity. bioRxiv. 2020. Epub 2020/06/27. doi: 10.1101/2020.06.12.148726. PubMed

608 PMID: 32587973; PMCID: PMC7310631.

607

6. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike:
mechanisms of coronavirus cross-species transmission. Journal of virology. 2010;84(7):313446. Epub 2009/11/13. doi: 10.1128/JVI.01394-09. PubMed PMID: 19906932; PMCID:
2838128.

Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly
identified coronavirus 2019-nCoV. Journal of medical virology. 2020;92(4):433-40. Epub
2020/01/23. doi: 10.1002/jmv.25682. PubMed PMID: 31967321.

8. Sidney J, Southwood S, Moore C, Oseroff C, Pinilla C, Grey HM, Sette A. 616 Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. 617 618 Curr Protoc Immunol. 2013;Chapter 18:Unit 18 3. Epub 2013/02/09. doi: 10.1002/0471142735.im1803s100. PubMed PMID: 23392640; PMCID: PMC3626435. 619

9. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee HG,
Falk K, Rotzschke O, Takiguchi M, Kubo RT, et al. Several HLA alleles share overlapping
peptide specificities. Journal of immunology. 1995;154(1):247-59. Epub 1995/01/01.
PubMed PMID: 7527812.

Parker MD, Lindsey BB, Leary S, Gaudieri S, Chopra A, Wyles M, Angyal A, Green
LR, Parsons P, Tucker RM, Brown R, Groves D, Johnson K, Carrilero L, Heffer J, Partridge
DG, Evans C, Raza M, Keeley AJ, Smith N, Filipe ADS, Shepherd JG, Davis C, Bennett S,
Sreenu VB, Kohl A, Aranday-Cortes E, Tong L, Nichols J, Thomson EC, Wang D, Mallal S,
De Silva TI. Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data.
Genome Research. 2021;31(4):645-58. doi: 10.1101/gr.268110.120.

I1. Jenjaroenpun P, Wanchai V, Ono-Moore KD, Laudadio J, James LP, Adams SH,
Prior F, Nookaew I, Ussery DW, Wongsurawat T. Two SARS-CoV-2 Genome Sequences of
Isolates from Rural U.S. Patients Harboring the D614G Mutation, Obtained Using Nanopore

633 Sequencing. Microbiol Resour Announc. 2020;10(1). Epub 2020/12/19. doi:
634 10.1128/MRA.01109-20. PubMed PMID: 33334896.

Franco-Muñoz C, Álvarez-Díaz DA, Laiton-Donato K, Wiesner M, Escandón P,
Usme-Ciro JA, Franco-Sierra ND, Flórez-Sánchez AC, Gómez-Rangel S, RodríguezCalderon LD, Barbosa-Ramirez J, Ospitia-Baez E, Walteros DM, Ospina-Martinez ML,
Mercado-Reyes M. Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2
circulating in South America. Infect Genet Evol. 2020;85:104557-. Epub 2020/09/17. doi:
10.1016/j.meegid.2020.104557. PubMed PMID: 32950697.

Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L,
Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell
AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman
P, Korber B, Kiepiela P, Walker B, Goulder P. Transmission and accumulation of CTL
escape variants drive negative associations between HIV polymorphisms and HLA. J Exp
Med. 2005;201(6):891-902. Epub 2005/03/23. doi: 10.1084/jem.20041455. PubMed PMID:
15781581; PMCID: 2213090.

Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y,
Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P,
Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H,
Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ. HIV
evolution: CTL escape mutation and reversion after transmission. Nature medicine.
2004;10(3):282-9. Epub 2004/02/11. doi: 10.1038/nm992. PubMed PMID: 14770175.

Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of
HIV-1 adaptation to HLA-restricted immune responses at a population level. Science.
2002;296(5572):1439-43. Epub 2002/05/25. doi: 10.1126/science.1069660. PubMed PMID:
12029127.

658 16. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims

659 S, Dempsey E, Freitas E, Lea S, McKiernan S, Norris S, Long A, Kelleher D, Klenerman P.

660 Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus

661 infection. Gut. 2011;60(11):1563-71. Epub 2011/05/10. doi: 10.1136/gut.2010.228403.

- 662 PubMed PMID: 21551190; PMCID: 3184218.
- Rubnitz J, Subramani S. The minimum amount of homology required for homologous
 recombination in mammalian cells. Molecular and cellular biology. 1984;4(11):2253-8. Epub
 1984/11/01. doi: 10.1128/mcb.4.11.2253. PubMed PMID: 6096689; PMCID: 369052.
- Sola I, Moreno JL, Zuniga S, Alonso S, Enjuanes L. Role of nucleotides immediately 18. 666 667 flanking the transcription-regulating sequence core in coronavirus subgenomic mRNA synthesis. 668 Journal of virology. 2005;79(4):2506-16. Epub 2005/02/01. doi: 10.1128/JVI.79.4.2506-2516.2005. PubMed PMID: 15681451; PMCID: 546574. 669

670 19. Parker MD, Lindsey BB, Leary S, Gaudieri S, Chopra A, Wyles M, Angyal A, Green

671 LR, Parsons P, Tucker RM, Brown R, Groves D, Johnson K, Carrilero L, Heffer J, Partridge

DG, Evans C, Raza M, Keeley AJ, Smith N, Filipe ADS, Shepherd JG, Davis C, Bennett S,

673 Sreenu VB, Kohl A, Aranday-Cortes E, Tong L, Nichols J, Thomson EC, Consortium C-GU,

Wang D, Mallal S, de Silva TI. Subgenomic RNA identification in SARS-CoV-2 genomic

675 sequencing data. Genome Res. 2021;31(4):645-58. Epub 2021/03/17. doi:
676 10.1101/gr.268110.120. PubMed PMID: 33722935; PMCID: PMC8015849.

Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARSCoV-2 Transcriptome. Cell. 2020;181(4):914-21 e10. Epub 2020/04/25. doi:
10.1016/j.cell.2020.04.011. PubMed PMID: 32330414; PMCID: PMC7179501.

Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski
LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S,
Martinez DR, Atveo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A,

683 Greenhouse J, Taylor T, Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J,

Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C,

685 Kordana N, Li Z, Lifton MA, Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP,

686 Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG,

687 Barouch DH. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

688 Science. 2020;369(6505):812-7. doi: 10.1126/science.abc4776.

689 22. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer

D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann

691 R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients

with COVID-2019. Nature. 2020;581(7809):465-9. doi: 10.1038/s41586-020-2196-x.

693 23. Lorenz R, Bernhart SH, Honer Zu Siederdissen C, Tafer H, Flamm C, Stadler PF,

Hofacker IL. ViennaRNA Package 2.0. Algorithms for molecular biology : AMB. 2011;6:26.

Epub 2011/11/26. doi: 10.1186/1748-7188-6-26. PubMed PMID: 22115189; PMCID:
3319429.

Laing C, Wen D, Wang JT, Schlick T. Predicting coaxial helical stacking in RNA
junctions. Nucleic acids research. 2012;40(2):487-98. Epub 2011/09/16. doi:
10.1093/nar/gkr629. PubMed PMID: 21917853; PMCID: 3258123.

de la Pena M, Dufour D, Gallego J. Three-way RNA junctions with remote tertiary
contacts: a recurrent and highly versatile fold. Rna. 2009;15(11):1949-64. Epub 2009/09/11.

doi: 10.1261/rna.1889509. PubMed PMID: 19741022; PMCID: 2764472.

Hua L, Song Y, Kim N, Laing C, Wang JT, Schlick T. CHSalign: A Web Server That
Builds upon Junction-Explorer and RNAJAG for Pairwise Alignment of RNA Secondary
Structures with Coaxial Helical Stacking. PloS one. 2016;11(1):e0147097. Epub 2016/01/21.

doi: 10.1371/journal.pone.0147097. PubMed PMID: 26789998; PMCID: 4720362.

Chapman EG, Moon SL, Wilusz J, Kieft JS. RNA structures that resist degradation by
Xrn1 produce a pathogenic Dengue virus RNA. eLife. 2014;3:e01892. Epub 2014/04/03. doi:

10.7554/eLife.01892. PubMed PMID: 24692447; PMCID: 3968743.

710 28. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott

K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M,

712 Mallal SA. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic

713 hepatitis C virus infection. J Virol. 2006;80(22):11094-104. Epub 2006/10/31. doi:

714 10.1128/JVI.00912-06. PubMed PMID: 17071929; PMCID: 1642167.

P. Brumme ZL, Kinloch NN, Sanche S, Wong A, Martin E, Cobarrubias KD, Sandstrom
P. Levett PN, Harrigan PR, Joy JB. Extensive host immune adaptation in a concentrated
North American HIV epidemic. Aids. 2018;32(14):1927-38. Epub 2018/07/27. doi:
10.1097/QAD.00000000001912. PubMed PMID: 30048246; PMCID: 6125742.

30. Katoh J, Kawana-Tachikawa A, Shimizu A, Zhu D, Han C, Nakamura H, Koga M,
Kikuchi T, Adachi E, Koibuchi T, Gao GF, Brumme ZL, Iwamoto A. Rapid HIV-1 Disease
Progression in Individuals Infected with a Virus Adapted to Its Host Population. PloS one.
2016;11(3):e0150397. Epub 2016/03/10. doi: 10.1371/journal.pone.0150397. PubMed
PMID: 26953793; PMCID: 4783116.

Peng H, Yang LT, Wang LY, Li J, Huang J, Lu ZQ, Koup RA, Bailer RT, Wu CY.
Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein
in SARS-recovered patients. Virology. 2006;351(2):466-75. Epub 2006/05/13. doi:
10.1016/j.virol.2006.03.036. PubMed PMID: 16690096.

Yang Y, Yan W, Hall B, Jiang X. Characterizing transcriptional regulatory sequences
in coronaviruses and their role in recombination. bioRxiv. 2020. Epub 2020/06/27. doi:
10.1101/2020.06.21.163410. PubMed PMID: 32587968; PMCID: PMC7310624.

33. Sola I, Almazan F, Zuniga S, Enjuanes L. Continuous and Discontinuous RNA
Synthesis in Coronaviruses. Annual review of virology. 2015;2(1):265-88. Epub 2016/03/10.
doi: 10.1146/annurev-virology-100114-055218. PubMed PMID: 26958916; PMCID:
6025776.

34. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. Severe
acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and
nucleocapsid proteins function as interferon antagonists. Journal of virology. 2007;81(2):54857. Epub 2006/11/17. doi: 10.1128/JVI.01782-06. PubMed PMID: 17108024; PMCID:
PMC1797484.

35. Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARSCoV-2 is sensitive to type I interferon pretreatment. bioRxiv. 2020. Epub 2020/06/09. doi:
10.1101/2020.03.07.982264. PubMed PMID: 32511335; PMCID: PMC7239075.

36. Hu Y, Li W, Gao T, Cui Y, Jin Y, Li P, Ma Q, Liu X, Cao C. The Severe Acute
Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by
Interfering with TRIM25-Mediated RIG-I Ubiquitination. Journal of virology. 2017;91(8).
Epub 2017/02/06. doi: 10.1128/JVI.02143-16. PubMed PMID: 28148787; PMCID:
PMC5375661.

Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM,
Ward AM, Gubler DJ, Harris E, Garcia-Blanco MA, Ooi EE. Dengue subgenomic RNA
binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science.
2015;350(6257):217-21. Epub 2015/07/04. doi: 10.1126/science.aab3369. PubMed PMID:
26138103; PMCID: PMC4824004.

38. Zuniga S, Cruz JL, Sola I, Mateos-Gomez PA, Palacio L, Enjuanes L. Coronavirus
nucleocapsid protein facilitates template switching and is required for efficient transcription.

- Journal of virology. 2010;84(4):2169-75. Epub 2009/12/04. doi: 10.1128/JVI.02011-09.
 PubMed PMID: 19955314; PMCID: PMC2812394.
- 757 39. Thorne LG, Bouhaddou M, Reuschl A-K, Zuliani-Alvarez L, Polacco B, Pelin A,
- 758 Batra J, Whelan MVX, Ummadi M, Rojc A, Turner J, Obernier K, Braberg H, Soucheray M,
- 759 Richards A, Chen K-H, Harjai B, Memon D, Hosmillo M, Hiatt J, Jahun A, Goodfellow IG,
- 760 Fabius JM, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Swaney DL, Garcia-
- 761 Sastre A, Jolly C, Towers GJ, Krogan NJ. Evolution of enhanced innate immune evasion by
- the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv. 2021.
- 40. Guo K, Barrett BS, Mickens KL, Hasenkrug KJ, Santiago ML. Interferon Resistance
 of Emerging SARS-CoV-2 Variants. bioRxiv. 2021.
- Jiang HW, Zhang HN, Meng QF, Xie J, Li Y, Chen H, Zheng YX, Wang XN, Qi H,
 Zhang J, Wang PH, Han ZG, Tao SC. SARS-CoV-2 Orf9b suppresses type I interferon
 responses by targeting TOM70. Cell Mol Immunol. 2020;17(9):998-1000. Epub 2020/07/31.
- doi: 10.1038/s41423-020-0514-8. PubMed PMID: 32728199; PMCID: PMC7387808.
- 42. Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, Cupic A,
- 770 Makio T, Mei M, Moreno E, Danziger O, White KM, Rathnasinghe R, Uccellini M, Gao S,
- 771 Aydillo T, Mena I, Yin X, Martin-Sancho L, Krogan NJ, Chanda SK, Schotsaert M, Wozniak
- 772 RW, Ren Y, Rosenberg BR, Fontoura BMA, Garcia-Sastre A. SARS-CoV-2 Orf6 hijacks
- Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad
- 774 Sci U S A. 2020;117(45):28344-54. Epub 2020/10/25. doi: 10.1073/pnas.2016650117.
- 775 PubMed PMID: 33097660; PMCID: PMC7668094.
- 43. Oh SJ, Shin OS. SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor
 Pathways to Inhibit the Induction of Interferon Response. Cells. 2021;10(3). Epub
 2021/04/04. doi: 10.3390/cells10030530. PubMed PMID: 33801464; PMCID: PMC7999926.

- 44. Parker MD, Lindsey BB, Shah DR, Hsu S, Keeley AJ, Partridge DG, Leary S, Cope
- A, State A, Johnson K, Ali N, Raghei R, Heffer J, Smith N, Zhang P, Gallis M, Louka SF,
- 781 Whiteley M, Foulkes BH, Christou S, Wolverson P, Pohare M, Hansford SE, Green LR,
- 782 Evans C, Raza M, Wang D, Gaudieri S, Mallal S, , de Silva TI. Altered Subgenomic RNA
- 783 Expression in SARS-CoV-2 B.1.1.7 Infections. bioRxiv. 2021.
- 45. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR,
- 785 Dull P, Plotkin SA. Evidence for antibody as a protective correlate for COVID-19 vaccines.
- 786 Vaccine. 2021;39(32):4423-8. doi: 10.1016/j.vaccine.2021.05.063.
- 46. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K,
- Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of
 immune protection from symptomatic SARS-CoV-2 infection. Nature medicine.
 2021;27(7):1205-11. doi: 10.1038/s41591-021-01377-8.
- 47. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal
- Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y,
- 793 Regev-Yochay G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
- New England Journal of Medicine. 2021. doi: 10.1056/nejmoa2109072.

795

797 FIGURES






Fig 1. Proportion of weekly deposited SARS-CoV-2 sequences globally (n=455774). The
 D614G (B.1) variant has become one of the dominant forms globally. Note a small
 proportion of deposited sequences did not include information regarding specific collection
 date and as such were excluded.





Fig 2. Proportion of weekly deposited SARS-CoV-2 sequences by region. The proportion
 of R203/G204 to K203/R204 sub-variants of the D614G variant differs in different regions
 with recent increases in the frequency of new variants.




820

Fig 3. The configuration of canonical sgRNAs and the novel non-canonical nucleocapsid

sgRNA (N*) in SARS-CoV-2. The bottom bar illustrates the presence of the leader sequence (blue text) followed by the transcription-regulating sequence (TRS; red text) within the genomic sequence that continues into the first ORF 1a. The presence of other canonical sgRNA transcripts in which the leader sequence and TRS precede the start codon (methionine; pink) of the other proteins are shown. The presence of the novel non-canonical sgRNA transcript containing the K203/R204 polymorphisms (N*) is shown. The ARTIC primer locations and resultant amplicons are shown.

- 829
- 830

832





835


Fig 4. Exploration of sgRNAs in 981 samples from Sheffield, UK. A. A heatmap showing 836 837 presence or absence of sgRNAs from different ORFs. K203/R204 (KR)-containing sequences have evidence of the novel truncated N ORF sgRNA (N*, red, 233/553, 42%). An ORF 838 sgRNA was deemed present if we could find >=1 read in support. Heatmap is ordered by the 839 presence or absence of the novel sgRNA. There were a total of 448 R203/G204 (RG)-840 containing sequences and 1 had evidence of a novel sgRNA (likely false positive, Fig S2). B. 841 Significantly higher (Mann-Whitney U p < 2.2e-16) total sgRNA in KR-containing compared 842 to RG-containing sequences. C. Sub-genomic RNA is significant increased in KR-containing 843

compared to RG-containing sequences for a number of ORFs, most notably nucleocapsid (N; 844 Mann-Whitney U p = 2.06e-37 corrected for multiple testing using the Holm method). Y-axis 845 denotes square root transformed sub-genomic reads normalized to 100,000 genomic reads 846 from the same ARTIC amplicon. D. There is no difference in genomic RNA levels 847 (normalized to total mapped reads) between KR- and RG-containing sequences. *novel 848 sgRNA, ORF10 and ORF1a are excluded from this analysis due to ORF10 not being 849 expressed, difficulty in discriminating ORF1a sgRNA from genomic RNA and the novel 850 truncated N sgRNA is only being present in KR-containing sequences. *** < 0.001, ** < 851 0.01, * < 0.05. All p values shown are following correction for multiple testing with the 852 Holm method. 853

854

855







861

862

863

864

865

866

867

868

869

870

Fig 5. Spike 614 and Nucleocapsid 203/204 Status, Diagnostic Metrics and level of subgenomic and genomic RNA. A. E gene cycle threshold (CT) normalized to RNAseP CT stratified by variant status in N = 478 individuals from Sheffield dataset with day of symptom onset data available. This normalization was done to combine and display E gene CT data from two different extraction protocols. Y-axis reversed to aid interpretation, as lower normalized CT values equal higher virus levels. **B.** Normalized E gene CT vs the day of sampling from day of symptom onset. P values provided are from a generalized multivariable linear regression model (GLM) for the difference in normalized E gene CT value between samples containing each variant, with extraction method and day of illness included in the model (Table S6) **C.** Normalized (per 1000 genomic reads) sgRNA levels for ORFs S and N. **D.** Normalized (per 100,000 mapped reads) genomic RNA levels for ORFs S and N.

- 871 872
- 873
- 874